H.C. Wainwright analyst Andrew Fein upgraded Fulcrum Therapeutics (FULC – Research Report) to a Buy today and set a price target of $14.00. The company’s shares closed yesterday at $5.43.
According to TipRanks, Fein is an analyst with an average return of -3.1% and a 37.40% success rate. Fein covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Biogen, and Vertex Pharmaceuticals.
In addition to H.C. Wainwright, Fulcrum Therapeutics also received a Buy from Stifel Nicolaus’s Dae Gon Ha in a report issued yesterday. However, on the same day, Bank of America Securities reiterated a Sell rating on Fulcrum Therapeutics (NASDAQ: FULC).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $15.00 and a one-year low of $2.25. Currently, Fulcrum Therapeutics has an average volume of 1.91M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Read More on FULC:
- Fulcrum Therapeutics (NASDAQ:FULC) Skyrockets After FDA Lifts Clinical Hold on Sickle Cell Disease Candidate
- FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics names Alan Musso as CFO
- Fulcrum Therapeutics expects cash to fund operations into mid-2025
